Moderate riskFDA DeviceClass II

Meridian Bioscience Revogene C. difficile assay recalled for declining performance and false-negative results

Meridian Bioscience's Revogene C. difficile diagnostic test (a lab assay used with the Revogene instrument) may show declining accuracy over time in certain lots. This could produce false-negative results, meaning the test might not detect C. difficile infection when it is present.

From the FDA notice · Read the official notice ↗

What to do

  1. Stop using affected lots: 410300U195, 410300U196, 410300U197, 410300U201
  2. Contact Meridian Bioscience for guidance on replacement or alternative testing
  3. Review recent test results from these lots with your lab director or healthcare provider

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300
Sold in
Nationwide
Made for
All ages (under 100 years)

Details

Units affected
211 units
Illnesses reported
None reported
Manufactured in
3471 River Hills Dr, Cincinnati, OH, United States
Classification
Class II
Recall number
Z-1019-2026

In the FDA's words

Description
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 The affected lots show a decline in performance over time, which may lead to false-negative results. UDI-DI: 00840733102349; Lot Numbers: 410300U195, 410300U196, 410300U197, 410300U201 Distribution: US Nationwide distribution and the OUS country of Italy. Affected quantity: 211 units
Hazard
The affected lots show a decline in performance over time, which may lead to false-negative results.

Related topics